Breakthroughs in Genitourinary Cancers – Insights from ESMO 2024. White Paper based on late-breaking abstracts presented in Barcelona. The 2024 European Society for Medical Oncology Congress in Barcelona, ESMO 2024, served as a pivotal platform for unveiling breakthroughs and addressing ongoing challenges in Genitourinary Cancers. This white paper dives deep into the transformative potential of…
Read more
Breakthroughs in Prostate Cancer – Insights from ESMO 2024. White Paper based on late-breaking abstracts presented in Barcelona. The 2024 European Society for Medical Oncology Congress in Barcelona, ESMO 2024, served as a pivotal platform for unveiling breakthroughs and addressing ongoing challenges in prostate cancer care and research. Prostate cancer took center stage, with sessions…
Read more
Breakthroughs in Lung & Other Thoracic Cancers – Insights from ESMO 2024. White Paper based on late-breaking abstracts presented in Barcelona. The 2024 European Society for Medical Oncology Congress in Barcelona, ESMO 2024, provided a pivotal venue for showcasing breakthroughs and addressing persistent challenges in cancer care and research. Non-metastatic non-small cell lung cancer (NSCLC)…
Read more
Breakthroughs in Upper Gastrointestinal Tumours – Insights from ESMO 2024. White Paper based on late-breaking abstracts presented in Barcelona. Upper gastrointestinal (GI) tumours, including hepatocellular carcinoma (HCC), gastric cancer, and esophageal cancer, were a major focus at ESMO 2024, with sessions dedicated to advancing therapeutic strategies, improving patient outcomes, and addressing quality-of-life concerns. This white…
Read more
Breakthroughs in Breast Cancer – Insights from ESMO 2024. White Paper based on late-breaking abstracts presented in Barcelona. Early-stage breast cancer, among the most frequently diagnosed cancers globally, was a key focus at this year’s ESMO conference, with sessions dedicated to advancing novel therapeutic strategies, improving personalized treatment approaches, and tackling survivorship challenges. “Breakthroughs in Breast…
Read more
Breakthroughs in Melanoma – Insights from ESMO 2024. White Paper based on late-breaking abstracts presented in Barcelona. The advancements in melanoma therapies presented at this year’s ESMO conference mark a transformative shift in the treatment landscape, with Real-World Evidence (RWE) playing a pivotal role in personalizing patient care. By integrating real-world data with clinical trial…
Read more
Evaluating ICDs’ Role in Reducing Sudden Cardiac Death Among High-Risk Patients OXON Epidemiology’s latest study, recently featured in JAMA Cardiology, provides critical insights into the effectiveness of implantable cardioverter-defibrillators (ICDs) compared to amiodarone in reducing sudden cardiac death among patients with chronic Chagas cardiomyopathy. Known as the CHAGASICS Randomized Clinical Trial, the study enrolled 323…
Read more
REAL WORLD EVIDENCE NEEDS IN ONCOLOGY: Gastroesophageal Cancer White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid. The varying nature of gastroesophageal cancer, spanning from localized, indolent tumors to aggressive, metastatic forms, coupled with the emergence of resistance to established treatments, emphasizes the urgent requirement for ongoing research and clinical…
Read more
REAL WORLD EVIDENCE NEEDS IN ONCOLOGY: Colorectal Cancer White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid. The complexity of colorectal cancer, spanning from localized, slow-growing tumors to aggressive forms, necessitates a diverse approach in both research and clinical management. Recent advancements in understanding its molecular and genetic underpinnings have…
Read more
REAL WORLD EVIDENCE NEEDS IN ONCOLOGY: Breast Cancer White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid. Metastatic breast cancer continues to be a significant health challenge in oncology. As the most common cancer in women worldwide, it imposes substantial healthcare burdens and necessitates continuous research and innovation in treatment…
Read more
